Richard R. DeLuca Jr. - 10 Aug 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: EVP&Pres, Merck Animal Heallth
Issuer ticker: MRK
Reported as of: 10 Aug 2026
Net transaction value: -$5,942,369
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:10:52 UTC
Prior SEC filing: 10 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.

Key filing fact

Richard R. DeLuca Jr. filed Form 4 for Merck & Co., Inc. (MRK) on 12 Aug 2026.

Key facts

This page summarizes Richard R. DeLuca Jr.'s Form 4 filing for Merck & Co., Inc. (MRK).
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 10 Aug 2026.
Current net transaction value: -$5,942,369.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001421339 Primary reporting owner

DeLuca Richard R.

Relationship: EVP&Pres, Merck Animal Heallth
Address: MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY
Signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK transaction

Common Stock

Sale

Transaction value: $2,710,951
Shares: -20,784
Change %: -13%
Price: $130.43
Shares after: 134,703
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

MRK transaction

Common Stock

Sale

Transaction value: $973,165
Shares: -7,410
Change %: -5.5%
Price: $131.33
Shares after: 127,293
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F2

MRK transaction

Common Stock

Sale

Transaction value: $718,261
Shares: -5,427
Change %: -4.3%
Price: $132.35
Shares after: 121,866
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F3

MRK transaction

Common Stock

Sale

Transaction value: $1,460,770
Shares: -11,099
Change %: -9.1%
Price: $131.61
Shares after: 110,767
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F4

MRK transaction

Common Stock

Sale

Transaction value: $79,222
Shares: -600
Change %: -0.54%
Price: $132.04
Shares after: 110,167
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.